Intensity Therapeutics Inc. Common stock (INTS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Intensity Therapeutics Inc. Common stock (INTS) is Moderate Underperform.

The composite score behind that read is -0.42, weighing +0.00 of bullish evidence against -0.42 bearish.

Intensity Therapeutics Inc. Common stock last closed at $3.45, +0.29% on the session.

Against the IVW growth benchmark the position is -0.63% over the forecast window.

The read is built from 12 underlying insights — 0 bullish and 12 bearish.

Agreement across those insights is 100%.

16 graded predictions for INTS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Intensity Therapeutics Inc. Common stock in the 9th percentile on return on equity, where 100 is best.

Intensity Therapeutics Inc. Common stock is classified under Health Care / Biotechnology, with a market capitalisation of $11.23M.

StockMap tracks Intensity Therapeutics Inc. Common stock as the 319th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Intensity Therapeutics Inc. Common stock ranks 316th of 344 in the group, against a group median of -0.21.